Verrica Pharmaceuticals Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Verrica Pharmaceuticals Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2017 to Q2 2024.
  • Verrica Pharmaceuticals Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $2.23M, a 44.3% increase year-over-year.
  • Verrica Pharmaceuticals Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $16M, a 207% increase year-over-year.
  • Verrica Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2023 was $14.4M, a 188% increase from 2022.
  • Verrica Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2022 was $4.99M, a 17.6% decline from 2021.
  • Verrica Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2021 was $6.05M, a 38.4% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $16M $2.23M +$684K +44.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $15.4M $2.07M +$978K +89.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 $14.4M $2.08M +$904K +77.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 $13.5M $9.66M +$8.25M +584% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $5.22M $1.54M +$459K +42.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $4.76M $1.09M -$222K -16.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 $4.99M $1.17M -$150K -11.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 $5.14M $1.41M -$68K -4.59% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $5.2M $1.09M -$763K -41.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $5.97M $1.32M -$87K -6.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $6.05M $1.32M -$5.02M -79.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-06
Q3 2021 $11.1M $1.48M +$250K +20.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $10.8M $1.85M +$596K +47.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $10.2M $1.4M +$405K +40.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $9.82M $6.34M +$5.54M +691% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-02
Q3 2020 $4.28M $1.23M +$326K +36% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $3.96M $1.25M +$406K +48% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 $3.55M $998K +$218K +27.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 $3.33M $802K +$148K +22.6% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-17
Q3 2019 $3.19M $905K +$222K +32.5% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $2.96M $846K +$67K +8.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $2.9M $780K +$645K +478% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $2.25M $654K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-13
Q3 2018 $683K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $779K +$777K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $135K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q2 2017 $2K* Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.